JP2013517330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517330A5 JP2013517330A5 JP2012550125A JP2012550125A JP2013517330A5 JP 2013517330 A5 JP2013517330 A5 JP 2013517330A5 JP 2012550125 A JP2012550125 A JP 2012550125A JP 2012550125 A JP2012550125 A JP 2012550125A JP 2013517330 A5 JP2013517330 A5 JP 2013517330A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29679110P | 2010-01-20 | 2010-01-20 | |
| US61/296,791 | 2010-01-20 | ||
| PCT/US2011/021939 WO2011091177A1 (en) | 2010-01-20 | 2011-01-20 | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013517330A JP2013517330A (ja) | 2013-05-16 |
| JP2013517330A5 true JP2013517330A5 (enExample) | 2014-03-06 |
Family
ID=44307212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550125A Pending JP2013517330A (ja) | 2010-01-20 | 2011-01-20 | 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9023997B2 (enExample) |
| EP (1) | EP2525813B1 (enExample) |
| JP (1) | JP2013517330A (enExample) |
| AU (1) | AU2011207253B2 (enExample) |
| CA (1) | CA2787783A1 (enExample) |
| WO (1) | WO2011091177A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI544077B (zh) | 2009-03-19 | 2016-08-01 | 中外製藥股份有限公司 | Antibody constant region change body |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| JP5947727B2 (ja) * | 2010-01-20 | 2016-07-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節 |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP4624490A3 (en) | 2012-02-09 | 2025-11-05 | Chugai Seiyaku Kabushiki Kaisha | Modified fc region of antibody |
| US20150174203A1 (en) * | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| US10097315B2 (en) * | 2013-04-19 | 2018-10-09 | Qualcomm Incorporated | Group scheduling and acknowledgement for wireless transmission |
| CA2925256C (en) | 2013-09-27 | 2023-08-15 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| US9985802B2 (en) * | 2014-10-31 | 2018-05-29 | Qualcomm Incorporated | Channel estimation enhancements |
| EP3256163A4 (en) * | 2015-02-11 | 2018-10-10 | University Health Network | Methods and compositions for modulating lilr proteins |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
| US11787858B2 (en) | 2016-12-22 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Anti-LILRB3 antibodies and methods of use thereof |
| MY201995A (en) | 2018-07-09 | 2024-03-28 | Five Prime Therapeutics Inc | Antibodies binding to ilt4 |
| EP3911680A4 (en) * | 2019-01-18 | 2022-09-07 | University Health Network | LILRB3 BINDING MOLECULES AND ASSOCIATED USES |
| CN113939316A (zh) * | 2019-03-28 | 2022-01-14 | 学校法人早稻田大学 | 细胞竞争调控剂 |
| KR20220154686A (ko) * | 2020-02-12 | 2022-11-22 | 바이오인벤트 인터내셔날 에이비 | Lilrb3 항체 분자 및 이의 용도 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61122292A (ja) | 1984-11-16 | 1986-06-10 | Teijin Ltd | 新規カルバサイクリン中間体の製法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE07012626T1 (de) | 1991-03-18 | 2010-01-21 | New York University | Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ATE204299T1 (de) | 1993-03-05 | 2001-09-15 | Bayer Ag | Humane monoklonale anti-tnf alpha antikörper |
| US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
| US20060078564A1 (en) | 2002-05-08 | 2006-04-13 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| WO2001055335A2 (en) | 2000-01-25 | 2001-08-02 | Hyseq, Inc. | Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides |
| AU2001239955A1 (en) | 2000-02-28 | 2001-09-12 | Hyseq, Inc. | Novel macrophage nucleic acids and polypeptides |
| WO2002000692A2 (en) | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: pd-1 ligands and uses therefor |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| AU2002360376B2 (en) * | 2001-11-14 | 2006-05-18 | Immunex Corporation | Modulation of LIR function to treat rheumatoid arthritis |
| US8071314B2 (en) | 2001-12-14 | 2011-12-06 | President And Fellows Of Harvard College | Immunocellular receptors related to neurological disorders and therapeutic uses thereof |
| KR101351122B1 (ko) | 2003-05-09 | 2014-01-14 | 듀크 유니버시티 | Ｃｄ２０-특이적 항체 및 이를 이용한 방법 |
| US20090215165A1 (en) | 2005-05-20 | 2009-08-27 | James Rance | High-level expression of recombinant antibody in a mammalian host cell |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| US8663634B2 (en) | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| EP1981522B1 (en) * | 2006-01-23 | 2012-09-12 | President and Fellows of Harvard College | Compositions and methods for enhancing neuronal plasticity and regeneration |
| BRPI0709917A2 (pt) | 2006-03-30 | 2011-07-05 | Novartis Ag | composições e métodos de uso para anticorpos de c-met |
| JP2009544761A (ja) | 2006-06-14 | 2009-12-17 | マクロジェニクス，インコーポレーテッド | 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法 |
| WO2008094176A2 (en) | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| KR20090082480A (ko) | 2006-11-14 | 2009-07-30 | 제넨테크, 인크. | 뉴런 재생의 조절인자 |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| EP3211011A1 (en) | 2007-11-16 | 2017-08-30 | Nuvelo, Inc. | Antibodies to lrp6 |
| KR20100109923A (ko) * | 2007-12-11 | 2010-10-11 | 제넨테크, 인크. | 뉴런 재생의 조정인자 |
| AU2009246443A1 (en) | 2008-05-13 | 2009-11-19 | Genentech, Inc. | Anti-PirB antibodies |
| US20090285803A1 (en) | 2008-05-13 | 2009-11-19 | Jasvinder Atwal | ANTI-PirB ANTIBODIES |
| CN102137869B (zh) | 2008-06-30 | 2018-07-06 | 宾夕法尼亚大学 | Fn14/TRAIL融合蛋白 |
| US9221895B2 (en) | 2009-03-13 | 2015-12-29 | The Trustees Of The University Of Pennsylvania | OX40/TRAIL fusion proteins |
| JP5996429B2 (ja) | 2009-09-03 | 2016-09-21 | ジェネンテック， インコーポレイテッド | 関節リウマチの治療、診断及びモニターするための方法 |
| JP5947727B2 (ja) | 2010-01-20 | 2016-07-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節 |
| US8609095B2 (en) * | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
| WO2012061620A1 (en) | 2010-11-04 | 2012-05-10 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| AR086287A1 (es) | 2011-05-05 | 2013-12-04 | Baylor Res Inst | Composicion inmunoestimulante, metodo |
| US20150174203A1 (en) | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
-
2011
- 2011-01-20 AU AU2011207253A patent/AU2011207253B2/en not_active Ceased
- 2011-01-20 CA CA2787783A patent/CA2787783A1/en not_active Abandoned
- 2011-01-20 US US13/574,307 patent/US9023997B2/en active Active
- 2011-01-20 JP JP2012550125A patent/JP2013517330A/ja active Pending
- 2011-01-20 WO PCT/US2011/021939 patent/WO2011091177A1/en not_active Ceased
- 2011-01-20 EP EP11735199.9A patent/EP2525813B1/en not_active Not-in-force
-
2015
- 2015-03-11 US US14/644,229 patent/US9828425B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022031635A5 (enExample) | ||
| JP2020180158A5 (enExample) | ||
| JP2021191763A5 (enExample) | ||
| JP2012502649A5 (enExample) | ||
| JP2017501711A5 (enExample) | ||
| JP2020039360A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| JP2010513539A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| JP2016507523A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2011517447A5 (enExample) | ||
| JP2010538608A5 (enExample) | ||
| JP2011519571A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2021101720A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP2015514094A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| JP2014503205A5 (enExample) | ||
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| JP2014526898A5 (enExample) |